This course has expired. View available courses.
Endocrinology
EB #2: New Basal Insulins Reduce the Incidence of Hypoglycemia
Hypoglycemia, although often unrecognized or discussed, is the most frequent side effect of insulin and can increased risk of adverse outcomes, cardiovascular events, and death, and has a significant impact on patients’ quality of life. In this expert brief, pharmacists Carol Wei and Tom Smiley will discuss technologies that can help patients and clinicians identify […]
DURATION
30 mins
PROFESSION
Nursing, Pharmacy
# OF CREDITS
0.5
ACCREDITATION
CCCEP
EXPIRY DATE
2022-07-26
Hypoglycemia, although often unrecognized or discussed, is the most frequent side effect of insulin and can increased risk of adverse outcomes, cardiovascular events, and death, and has a significant impact on patients’ quality of life. In this expert brief, pharmacists Carol Wei and Tom Smiley will discuss technologies that can help patients and clinicians identify and track glycemic variability and reduce hypoglycemic events. This expert brief will also address the newer, long-lasting insulins that have been shown to result in more stable control of fasting glucose levels with lower risk of hypoglycemia, especially nocturnal hypoglycemia.
Faculty
Tom Smiley, BScPhm, PharmD, CTE
Carol Wei, RPh BScPhm CDE APA
Bilal Hatoum, BSc.Pharm., RPh., APA., CDE.
Jahed Khoshnood, RPh, PharmD, BSc
Learning objectives
Upon completion of this continuing education program, participants will be better able to:
- Recognize the prevalence and incidence of hypoglycemia in patients with type 2 diabetes treated with insulin;
- Explain how continuous glucose monitoring can uncover hypoglycemia/hyperglycemia and glycemic variability;
- Discuss the reduction of hypoglycemia seen with the newer longer-acting basal insulins.